Dopamine is a catecholamine that acts both as a hormone and a brain neurotransmitter. Rather than an isolated "reward chemical," it is one side of a broader antagonism with serotonin, where the balance between the two amines, not either one alone, shapes mood and movement.[1]

Dopamine
alt=62-31-7 (dopamine hydrochloride, the most common medicinal form) 6923170 (dopamine hydrochloride)
62-31-7 (dopamine hydrochloride, the most common medicinal form)

6923170 (dopamine hydrochloride)

Abbreviation DA
Molecular formula C₈H₁₁NO₂

189.64 g/mol (hydrochloride salt)

Type Catecholamine (acts both as a neurotransmitter and a hormone)
Administration
Bioavailability
Synonyms 3,4-Dihydroxyphenethylamine

3-Hydroxytyramine Intropin (brand) Oxytyramine Prolactin-inhibiting factor (PIF)

Source Naturally synthesized in the body from the amino acid L-tyrosine (then L-DOPA → dopamine)

Main production sites as a hormone: adrenal medulla (small amounts) and certain hypothalamic neurons

Main production sites as a neurotransmitter: substantia nigra, ventral tegmental area (VTA), and arcuate nucleus of the hypothalamus

Exogenous/medicinal source: synthetic (used as intravenous drug in critical care)

Ray's verdict Generally helps
A functional antagonist of serotonin: where serotonin sedates, dopamine (and adrenalin) can lift mood and movement, making dopamine-raising drugs like bromocriptine a more logical "antidepressant" than SSRIs.

Dosing

[edit]

As an endogenous hormone/neurotransmitter, dopamine is not dosed directly except as an IV drug in critical-care settings under medical supervision; raising dopaminergic tone is generally approached via other drugs and nutrients rather than dosing dopamine itself.

History

[edit]

Etymology

[edit]

The name is a contraction of its full chemical name, dihydroxyphenylethylamine.

Dopamine was first synthesized in 1910, but its role as an independent neurotransmitter, rather than merely a precursor to noradrenaline and adrenaline, wasn't established until Arvid Carlsson's work in the late 1950s, for which he shared the 2000 Nobel Prize in Physiology or Medicine.

Dopamine's name derives from its chemical identity as 3,4-dihydroxyphenylethylamine. It was long considered only a precursor to noradrenaline before its independent role as a neurotransmitter was established in the mid-20th century, notably through its depletion in Parkinson's disease.

Structure/Chemical properties

[edit]

Dopamine is a catecholamine, synthesized from the amino acid tyrosine via L-DOPA. Structurally it is a phenethylamine with two adjacent hydroxyl groups on the benzene ring.

Function/Mechanism of Action

[edit]

Injecting serotonin never relieves depression, while adrenalin or dopamine sometimes does; SSRIs' mood effects, when they occur, are better explained by their raising the activity of these other amines than by any direct antidepressant action of serotonin itself.[1] Dopamine is "pretty generally a serotonin antagonist," and bromocriptine, though usually labeled a "dopamine agonist," produces effects clearly antagonistic to serotonin as well as opposing histamine and estrogen.[2]

In Parkinson's disease, the benefit of raising dopamine concentration may result from dopamine's antagonism of serotonin: anti-serotonin drugs can alleviate Parkinsonian symptoms, while 5-hydroxytryptophan, a serotonin precursor, worsens them.[1] In the substantia nigra, dopamine metabolism is linked to a free-radical-generating cycle that produces melanin, assumed to defend against the free radicals this cycle generates.[3]

A single dose of the adamantane derivative bromantane (ladasten) raised tyrosine hydroxylase mRNA and protein in the rat hypothalamus and striatum within 1.5-2 hours, along with higher dopamine and L-DOPA content in those regions, showing bromantane raises dopamine output by upregulating its own rate-limiting synthesis enzyme rather than by acting as a reuptake blocker or receptor agonist.[4]

In fruit flies, a single mushroom-body neuron turns hunger into fighting, and protein deprivation raised male aggression more strongly than sugar deprivation; dopamine input to this neuron falls with hunger, and two opposing dopamine receptors on it push its excitability up or down.[5]

Vitamin D and dopamine receptors

[edit]

In a placebo-controlled PET study of 18 healthy adults, the active vitamin D hormone calcitriol raised baseline D2/D3 dopamine receptor availability in the ventral striatum and dorsal putamen, and produced a larger amphetamine-induced drop in receptor availability (a marker of greater dopamine release) in the ventral striatum, substantia nigra, and dorsal caudate, direct human evidence that vitamin D status can shift dopaminergic tone.[6]

Vitamin A and dopamine receptors

[edit]

Retinoic acids bound to their receptors regulate expression of the dopamine D2 receptor (D2R) in brain and pituitary; the liganded retinoic acid receptors are essential for full D2R expression.[7] D2R-knockout mice lack those retinoic acid receptors and show a locomotor defect similar to that seen in Parkinson's disease. See Vitamin A.

Medical uses/Effects

[edit]

Ketamine antidepressant response in humans paired reduced serotonin release with increased dopamine signaling via upregulated 5-HT1B autoreceptors.[8] Persistent cAMP signaling in hypothalamic dopamine neurons encoded mating drive; serotonergic drugs that raise 5-HT blunt this dopaminergic motivation circuit and sexual behavior.[9] High-dose nicotinamide riboside raised NAD+ and NAD+/NADH in Parkinson patients with symptomatic motor improvement on MDS-UPDRS part III, supporting NAD augmentation as a dopaminergic circuit-relevant intervention.[10] A COVID-19/CNS comorbidity network spanning Alzheimer's, Parkinson's, multiple sclerosis, and autism converged on UCHL1 as a shared target, with simulations suggesting pregnenolone as one of two drug candidates.[11] Caudate serotonin dynamics during social exchange differentiate Parkinson disease from essential tremor more clearly than dopamine measures alone in recent neuroimaging work.[12] Thiamine derivative TTFD raises locomotor activity and arousal with dopaminergic mediation in animal models.[13]

Treatment-resistant depression

[edit]

Pramipexole added to ongoing antidepressants reduced treatment-resistant depression symptoms over 48 weeks versus placebo in a UK RCT, via a dopamine-agonist pathway distinct from serotonin reuptake inhibition.[14] Medicinally, intravenous dopamine (Intropin) is used in critical care to raise blood pressure and cardiac output in shock. Dopaminergic and dopamine-adjacent drugs used for mood and movement disorders, particularly those that raise dopamine or otherwise oppose serotonin such as bromocriptine, have a more coherent claim to being "antidepressant" than serotonin-raising drugs.[1]

Side/Adverse effects

[edit]

Excess dopaminergic stimulation from drugs can cause agitation, arrhythmia, and, in the case of IV dopamine, tissue damage if it extravasates from the vein. Dopamine depletion, as in Parkinson's disease, produces movement disorders linked to an underlying shift in the serotonin/dopamine balance rather than a dopamine deficiency in isolation.[1]

ADHD

[edit]

Nonmedicated adults with ADHD (n=53) showed lower dopamine transporter and D2/D3 receptor binding than controls (n=44) in nucleus accumbens, midbrain, and left caudate on PET; attention ratings correlated with D2/D3 in those regions.[15] MPQ Achievement (trait motivation) scored lower in ADHD adults and correlated with midbrain and accumbens D2/D3 and with accumbens DAT within the ADHD group.[16] TRβ-deficient mice show ADHD-like hyperactivity with low dopamine metabolic rates in caudate putamen and nucleus accumbens and low serotonin metabolic rates.[17] Chronic caffeine normalized elevated frontocortical and striatal dopamine transporter density and dopamine uptake in adolescent SHR (ADHD model) and improved attentional set-shifting and Y-maze performance; WKY controls were unaffected on those measures.[18]

Chronic adversity and dopamine synthesis

[edit]

Nociceptin neurons in the ventral tegmental area become highly active at behavioral "give-up" points during effortful reward pursuit and suppress dopamine, providing a neural substrate for learned helplessness and effort withdrawal.[19] In humans exposed to acute laboratory stress, PET imaging showed that low lifetime psychosocial adversity produced dopamine synthesis proportional to perceived threat, whereas high chronic adversity produced exaggerated threat perception with impaired stress-evoked dopamine production and blunted cortisol and blood-pressure responses.[20]

Light exposure and myopia

[edit]

Bright outdoor-level illumination slows experimentally induced myopia in chicks; the protective effect depends on retinal dopamine signaling, as dopamine antagonism abolishes light's protection against excessive eye elongation.[21]

Alzheimer's disease

[edit]

Dopamine neuron activation and L-DOPA raise neprilysin and clear β-amyloid plaques in Alzheimer's mouse models, with improved memory on chronic L-DOPA.[22]

Heavy metals and tyrosine hydroxylase

[edit]

Toxic metals can blunt dopaminergic tone through TH and related steps (rodent/in vitro unless marked). Lead inhibits TH activity in vitro and after 30-day oral exposure in rats. Lower TH activity means lower nucleus-accumbens dopamine markers.[23] Chronic aluminum drinking-water exposure lowers TH-immunoreactive neuron counts in the substantia nigra and reduces locomotor performance in rats.[24] Systemic cadmium reduced striatal dopaminergic activity (DOPAC/DA) in rats.[25] See Heavy metals, Lead, Aluminum, Parkinson.

Parkinson's disease

[edit]

Gut dysbiosis-associated microbes in Parkinson disease link to reduced riboflavin and biotin, supporting B-vitamin supplementation as a simple therapeutic strategy in affected patients.[26] Extracellular damaged mitochondrial DNA from IFNβ-deficient neurons activates TLR4, kills dopaminergic neurons, and transmits Parkinson-like motor and cognitive deficits when injected into healthy animals.[27] Impaired mitochondrial clearance (mitophagy) allows damaged mitochondria to accumulate in neurons, depleting energy and driving dopaminergic neuron loss in sporadic Parkinson's models.[28] A computational basal-ganglia model identifies energy deficiency in substantia nigra pars compacta neurons as a primary driver of dopaminergic cell loss in Parkinson's disease, preceding classic dopamine-transporter depletion and linking metabolic stress to α-synuclein aggregation and oxidative damage.[29] Castration-induced androgen loss raises nigral iNOS-derived nitric oxide, depletes GDNF, and causes dopaminergic neuron loss and motor deficits in mice; DHT pellets reversed these changes, and castration did not cause them in iNOS-knockout mice.[30]

Breast cancer

[edit]

In rats with chemically induced mammary tumors, prolactin-lowering ergolines including bromocriptine caused regression of established tumors, while an ergoline that does not lower prolactin had no effect.[31][32]

Thyroid-hormone-driven remodeling of motor cortex links metabolic state to exploratory behavior and striatal reward-related signaling, integrating dopaminergic motivation with systemic energy availability.[33]

In thyroidectomized male rats, dopamine turnover fell in the medial and lateral palisade zones of the median eminence (the external layer of the hypothalamic dopamine system that projects to the pituitary), while other regions showed mixed noradrenaline and dopamine changes.[34]

Dopamine, MAO-B, and obesity

[edit]

In a 2023 study, reactive astrocytes in the hypothalamus overexpress monoamine oxidase B (MAO-B), producing excess GABA that tonically suppresses GABRA5-positive neurons controlling fat thermogenesis; silencing astrocytic MAO-B, or blocking it pharmacologically with a selective MAO-B inhibitor, restored thermogenesis and reduced weight gain in obese mice without any change in food intake.[35] Since MAO-B is also the enzyme that degrades dopamine, inhibiting it (the same mechanism as the Parkinson's/anti-aging drug selegiline) raises dopamine tone as well as lowering local GABA.

Dopamine agonists and anhedonia

[edit]

Pharmacological dopamine modulation reversed chronic-stress-induced deficits in reward learning in an animal model, direct experimental support for dopamine agonists as a treatment for anhedonia (loss of pleasure/motivation) rather than relying on serotonergic antidepressants alone.[36] In healthy men, one low dose of a D2-receptor blocking drug lowered the effort spent to earn money. In a preregistered, randomized, double-blind, placebo-controlled trial of 203 right-handed men aged 18–35, 200 mg of the drug taken about 3 hours before testing cut button presses in a modified Effort-Expenditure for Rewards Task by about 4 per 20-second trial, after adjusting for motor speed.[37] The drop ran opposite to the preregistered prediction, which rested on low doses blocking mainly the presynaptic D2/D3 receptors that brake dopamine release, and so raising that release. Reward size and payout odds did not change the effect, and neither did trait extraversion. The drug group also tapped more slowly on unrewarded speed trials (right hand: 131 vs 137 maximum clicks), so part of the drop may be motor rather than motivational. This was a single human pharmacology trial in mostly student men, with one dose and no drug blood levels.[37]

In mice, gut bacteria shape the dopamine rise in the striatum, the brain's reward area, during exercise. Mice given antibiotics had a blunted dopamine rise and ran less, blocking dopamine receptors cut running in the same way, and bromocriptine restored running in the antibiotic-treated mice. During exercise the gut signal lowered striatal MAO-A, the enzyme that breaks dopamine down. This was a mouse study with no human data.[38]

Caffeine modulates dopaminergic, glutamatergic, and GABAergic transmission and has been reported to protect dopaminergic neurons in animal models.[39] Ascorbate status also matters for dopamine tone: deficiency lowered brain BH4 (needed for tyrosine hydroxylase) and monoamine levels in rats, and lowered dopamine release in the nucleus accumbens of mice.[40][41] Coffee can lower serum prolactin, which otherwise opposes dopaminergic tone; see Coffee.

Cocaine

[edit]

Template:Main Cocaine is a tropane alkaloid from the coca plant that blocks reuptake of noradrenaline and dopamine, raising extraneural concentrations of both. Traditional Andean coca-leaf chewing prevents altitude-related hypoglycemia and shows good dental health; the purified hydrochloride salt by contrast has acidic, cardiotoxic, and addictive effects at pharmacological doses. See Cocaine for dosing, mechanism, effects (cardiovascular, oral/dental, teratogenicity), and sourcing.

Parkinson's

[edit]

Parkinson's disease is a movement disorder with loss of dopamine neurons in the substantia nigra: tremor, rigidity, slow movement. The energy frame treats it as long-run oxidative failure with iron, unsaturated fat injury, and thyroid interaction. The brain has a large buffer against this loss before symptoms appear: in a primate model, mild parkinsonism only emerged once nigral dopamine neuron counts fell by about 14-23% (or striatal dopamine by 14-37%), and inferential human studies put the striatal dopamine reserve threshold at roughly 70% before motor deficits become apparent.[42]

Aluminum and nigral TH

[edit]

Chronic aluminum in drinking water reduces tyrosine hydroxylase–immunoreactive neuron counts in the rat substantia nigra and impairs locomotion, more strongly when exposure starts in utero.[43] Animal histology, not proof that environmental aluminum causes human Parkinson disease. See Aluminum and Dopamine.

Thyroid overlap

[edit]

Hypothyroidism can mimic Parkinsonism; Parkinsonism can hide hypothyroidism. Both need pulse, temperature, and clinical context, not a single lab.[44]

Iron and free radical chemistry appear in the degenerative picture. See Iron, Dopamine, Thyroid, PUFA.

Serotonin and hallucinations

[edit]

Most Parkinson's treatment targets dopamine loss directly, but visual hallucinations, which affect roughly three-quarters of people with Parkinson's at some point, are being tested against a serotonin-antagonist approach instead: a UK phase 2 trial (Parkinson's UK/UCL) is giving ondansetron, a selective 5-HT3 serotonin antagonist normally used for nausea, to see whether blocking serotonin reduces hallucination frequency and severity.[45] The trial was paused in early 2024 over safety concerns in the ondansetron arm and resumed in 2025 after review, so this is an open question under active investigation, not a settled finding.[45]

Gut and antibiotics

[edit]

In Peat's frame, stress damages the intestinal barrier and lets bacterial endotoxin into the blood, where it drives nitric oxide, serotonin and other excitatory mediators that can also form in the brain, making diet, laxatives and anti-inflammatory substances plausible treatments for Parkinson's disease.[46]

In a UK primary-care records study, people with five or more penicillin courses in the 1 to 5 years before diagnosis had modestly lower odds of Parkinson's disease, while repeated antifungal courses went with higher odds.[47] A Finnish nationwide case-control study linked several oral antibiotics classes to higher odds instead, so the antibiotic signal in Parkinson's stays inconsistent and observational.[48] Doxycycline spared nigral dopamine neurons and striatal terminals in 6-OHDA mice and damped the astrocyte and microglia response.[49] It remodels α-synuclein oligomers into non-toxic off-pathway species[50] and cuts aggregate number and size in cells, with dopaminergic recovery in a C. elegans model.[51] In eight levodopa-treated patients, 200 mg/day for 12 weeks reduced dyskinesia scores.[52]

Practice

[edit]

Medical neurology for diagnosis and drugs. Metabolic support: thyroid context, lower seed oils, sugar oxidation, light.

In a small human study, three 10-minute sessions of breathing low-level CO₂ in on-off cycles drew more cerebrospinal fluid into the brain and raised blood levels of brain-derived proteins, including α-synuclein, in people with Parkinson's disease and in healthy older adults; the fluid inflow was smaller in the Parkinson's group.[53] In rotenone-poisoned mice, high CO₂ inhalation restored exploratory behavior, locomotion and coordination, and nigrostriatal areas survived on histology.[54]

Testimonies

[edit]

A family member's tremor, speech and reflux improved with daily one-hour CO₂ baths, later combined with low-dose doxycycline, while levodopa continued (n=1).[55] See Testimonies.

References

[edit]
  1. ↑ 1.0 1.1 1.2 1.3 1.4 Ray Peat, "Serotonin, Depression, and Aggression: The Problem of Brain Energy," raypeat.com.
  2. ↑ Ray Peat, "Serotonin, Depression, and Aggression: The Problem of Brain Energy," raypeat.com.
  3. ↑ Ray Peat, "Age Pigment: Cause and Effect of Aging and Stress," Ray Peat Newsletter.
  4. ↑ Mikhaylova M, Vakhitova JV, Yamidanov RS, Salimgareeva MKh, Seredenin SB, Behnisch T. "The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats." Neuropharmacology. 2007;53(5):601-608. PMID 17854844.
  5. ↑ Wang J, Lv Q, Gao Y, Yang Y, Ning J, Chen D, Wang W, Zhang X, Li Z, Shao Y, Liu Q, Liang Q, Sun Y. "Hunger states modulate aggression via opposing dopamine pathways." Nature Communications. 2026. doi:10.1038/s41467-026-76608-y. PMID 42811007. Drosophila males; hangry neuron MBON11, dopamine from PPL101; Dop1R1 (cAMP) and Dop1R2 (calcium) knockdown in MBON11 raised or lowered lunging respectively.
  6. ↑ Worhunsky PD, Mignosa MM, Gallezot JD, Pittman B, Nabulsi NB, Stryjewski A, Jalilian-Khave L, Trinko R, DiLeone RJ, Carson RE, Malison RT, Potenza MN, Angarita GA. "Vitamin D's Capacity to Increase Amphetamine-Induced Dopamine Release in Healthy Humans: A Clinical Translational [11C]-PHNO Positron Emission Tomography Study." Biol Psychiatry. 2025;97(6):651-658. PMID 39395473.
  7. ↑ Wolf G. "Vitamin A functions in the regulation of the dopaminergic system in the brain and pituitary gland," Nutr Rev. 1998;56(12):354-5. doi:10.1111/j.1753-4887.1998.tb01678.x. PMID 9884583.
  8. ↑ Lundberg J, et al. "Ketamine, 5-HT1B, and dopamine," Transl Psychiatry. 2020. doi:10.1038/s41398-020-0844-4.
  9. ↑ Zhang SX, et al. "Hypothalamic dopamine neurons motivate mating," Nature. 2021. doi:10.1038/s41586-021-03845-0.
  10. ↑ Brunt ER, et al. "Nicotinamide riboside in Parkinson disease," Nat Commun. 2023. doi:10.1038/s41467-023-43514-6.
  11. ↑ Qian J, et al. "Drug Repurposing for COVID-19 by Constructing a Comorbidity Network with Central Nervous System Disorders," Int J Mol Sci. 2024. PMID 39201608.
  12. ↑ Hartle E, et al. "Caudate serotonin in Parkinson disease," Nat Commun. 2025. doi:10.1038/s41467-025-63079-w.
  13. ↑ Hata T, et al. "TTFD promotes arousal and activity," J Physiol Sci. 2025. doi:10.1016/j.jphyss.2024.100001.
  14. ↑ Browning M, et al. "Pramipexole for treatment-resistant depression," Lancet Psychiatry. 2025. doi:10.1016/S2215-0366(25)00194-4. PMID 40602411.
  15. ↑ Volkow ND, Wang GJ, Kollins SH, et al. "Evaluating dopamine reward pathway in ADHD: clinical implications," JAMA. 2009;302(10):1084-1091. PMID 19738093.
  16. ↑ Volkow ND, Wang GJ, Newcorn JH, et al. "Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway," Mol Psychiatry. 2011;16(11):1147-1154. PMID 20856250.
  17. ↑ Ookubo M, Sadamatsu M, Yoshimura A, et al. "Aberrant Monoaminergic System in Thyroid Hormone Receptor-β Deficient Mice as a Model of Attention-Deficit/Hyperactivity Disorder," Int J Neuropsychopharmacol. 2015;18(7):pyv004. PMID 25612897.
  18. ↑ Pandolfo P, Machado NJ, Köfalvi A, Takahashi RN, Cunha RA. "Caffeine regulates frontocorticostriatal dopamine transporter density and improves attention and cognitive deficits in an animal model of attention deficit hyperactivity disorder," Eur Neuropsychopharmacol. 2013;23(4):317-328. PMID 22561003.
  19. ↑ Bruchas MR, et al. "Nociceptin and behavioral demotivation," Cell. 2019. doi:10.1016/j.cell.2019.07.014.
  20. ↑ Bloomfield MA, et al. "The effects of psychosocial stress on dopaminergic function and the acute stress response," eLife. 2019;8:e46797. PMID 31711569.
  21. ↑ Ashby RS, Schaeffel F. "Bright light and lens compensation in chicks," Invest Ophthalmol Vis Sci. 2010. doi:10.1167/iovs.09-4689.
  22. ↑ Saido TC, et al. "Dopamine signaling promotes neprilysin-mediated degradation of amyloid-β," Sci Signal. 2024;17(823):eadk1822. doi:10.1126/scisignal.adk1822.
  23. ↑ Jadhav AL, Ramesh GT. "Pb-induced alterations in tyrosine hydroxylase activity in rat brain," Mol Cell Biochem. 1997;175(1-2):137-41. PMID 9350044.
  24. ↑ Erazi H, Ahboucha S, Gamrani H. "Chronic exposure to aluminum reduces tyrosine hydroxylase expression in the substantia nigra and locomotor performance in rats," Neurosci Lett. 2011;487(1):8-11. PMID 20884324.
  25. ↑ Desole MS, et al. "[Cadmium-induced changes in the activity of the dopaminergic and purinergic systems and in ascorbic acid catabolism in the rat striatum]," Clin Ter. 1991;137(4):229-34. PMID 1831089.
  26. ↑ Nishiwaki H, et al. "Gut microbes and B vitamins in Parkinson disease," NPJ Parkinsons Dis. 2024. doi:10.1038/s41531-024-00724-z.
  27. ↑ Ko E, et al. "Damaged mtDNA and Parkinson pathology," Mol Psychiatry. 2023. doi:10.1038/s41380-023-02251-4.
  28. ↑ Issazadeh-Navikas S, et al. "Mitophagy failure causes Parkinson's disease," Nature. 2021;599:650-655. doi:10.1038/s41586-021-04059-0.
  29. ↑ Muddapu VR, Chakravarthy VS. "Influence of energy deficiency on the subcellular processes of Substantia Nigra Pars Compacta cell for understanding Parkinsonian neurodegeneration," Sci Rep. 2021;11:374. PMID 33462293.
  30. ↑ Khasnavis S, Ghosh A, Roy A, Pahan K. "Castration induces Parkinson disease pathologies in young male mice via inducible nitric-oxide synthase," J Biol Chem. 2013. PMID 23744073. PMCID PMC3774356.
  31. ↑ Cassady JM, Floss HG. "Ergolines as potential prolactin and mammary tumor inhibitors," Lloydia. 1977. PMID 327183.
  32. ↑ Formelli F, et al. "Correlation between inhibitory effect on prolactin secretion and antitumor activity of new ergoline compounds on DMBA-induced tumors in rats," Eur J Cancer Clin Oncol. 1983. PMID 6416848. 50 to 60% regression of initial tumors.
  33. ↑ Hochbaum DR, et al. "Thyroid hormone remodels cortex for metabolism and exploration," Cell. 2024. doi:10.1016/j.cell.2024.07.041.
  34. ↑ Andersson K, Eneroth P. "Regression analysis of catecholamine utilization in discrete hypothalamic and forebrain regions of the male rat: effects of thyroidectomy," Acta Physiol Scand. 1985;123(1):105-119. PMID 3881891.
  35. ↑ Sa M, Yoo ES, Koh W, et al. "Hypothalamic GABRA5-positive neurons control obesity via astrocytic GABA," Nat Metab. 2023;5(9):1506-1525. PMID 37653043.
  36. ↑ Lamontagne SJ, Wash EM, Irwin SH, et al. "Effects of dopamine modulation on chronic stress-induced deficits in reward learning," Cogn Affect Behav Neurosci. 2022. doi:10.3758/s13415-022-01001-3.
  37. ↑ 37.0 37.1 Ohmann HA, Kuper N, Wacker J. "A low dosage of the dopamine D2-receptor antagonist sulpiride affects effort allocation for reward regardless of trait extraversion," Personal Neurosci. 2020;3:e7. doi:10.1017/pen.2020.7. PMID 32656492. β = −4.16, p = .007, mean 121 presses.
  38. ↑ Dohnalová L, Lundgren P, Carty JRE, et al. "A microbiome-dependent gut-brain pathway regulates motivation for exercise," Nature. 2022;612(7941):739-747. doi:10.1038/s41586-022-05525-z. PMID 36517598. PMCID PMC11162758.
  39. ↑ Alasmari F. "Caffeine induces neurobehavioral effects through modulating neurotransmitters," Saudi Pharm J. 2020;28(4):445-451. PMCID:PMC7132598. PMID 32273803.
  40. ↑ Takeshita N, et al. "Deficiency of ascorbic acid decreases the contents of tetrahydrobiopterin in the liver and the brain of ODS rats," Neurosci Lett. 2020. PMID 31794791.
  41. ↑ Consoli DC, et al. "Ascorbate deficiency decreases dopamine release in gulo(-/-) and APP/PSEN1 mice," J Neurochem. 2021. PMID 32797675.
  42. ↑ Tabbal SD, Tian L, Karimi M, Brown CA, Loftin SK, Perlmutter JS. "Low nigrostriatal reserve for motor parkinsonism in nonhuman primates," Exp Neurol. 2012;237(2):355-362.
  43. ↑ Erazi H, Ahboucha S, Gamrani H. "Chronic exposure to aluminum reduces tyrosine hydroxylase expression in the substantia nigra and locomotor performance in rats," Neurosci Lett. 2011;487(1):8-11. PMID 20884324.
  44. ↑ Ray Peat, "TSH, temperature, pulse rate, and other indicators in hypothyroidism," raypeat.com.
  45. ↑ 45.0 45.1 "A clinical trial to explore the potential of ondansetron for treating hallucinations in people with Parkinson's disease" (TOP HAT trial), ISRCTN51996779; see also NCT04167813.
  46. ↑ Ray Peat's Newsletter, "Parkinson's disease: Some contexts for tremulous stiffness," March 2017.
  47. ↑ Pal G, Bennett L, Roy J, Nyandege A, Mouradian MM, Gerhard T, Horton DB. "Effects of antimicrobial exposure on the risk of Parkinson's disease", Parkinsonism & Related Disorders. 2024;127:107081. PMID 39098264. Nested case-control study in the Clinical Practice Research Datalink (CPRD); 12,557 cases matched by age, sex and index year to 80,804 controls. Penicillins, 5+ courses: 1 to 5 years prior OR 0.85; 6 to 10 years OR 0.84 (0.73 to 0.95); 11 to 15 years OR 0.87 (0.74 to 1.02, not significant). Two or more antifungal courses 1 to 5 years prior: OR 1.16 (1.06 to 1.27).
  48. ↑ Mertsalmi TH, Pekkonen E, Scheperjans F. "Antibiotic exposure and risk of Parkinson's disease in Finland: A nationwide case-control study", Movement Disorders. 2020;35(3):431-442. PMID 31737957. 13,976 cases, 40,697 controls; macrolides and lincosamides adjusted OR up to 1.42; antianaerobics and tetracyclines 10 to 15 years before index date also positive after multiple-comparison correction.
  49. ↑ Lazzarini M, Martin S, Mitkovski M, Vozari RR, Stühmer W, Del Bel E. "Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model", Glia. 2013;61(7):1084-1100. doi:10.1002/glia.22496. PMID 23595698. Mouse 6-OHDA model; reduced nigral and striatal dopaminergic loss, with lower microglia and astrocyte responses in globus pallidus and substantia nigra.
  50. ↑ González-Lizárraga F, Socías SB, Ávila CL, et al., Chehín RN. "Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species", Scientific Reports. 2017;7:41755. doi:10.1038/srep41755. PMID 28155912. PMC5290535. In vitro biophysics; off-pathway oligomers did not form fibrils and showed less membrane disruption and cell toxicity.
  51. ↑ Dominguez-Meijide A, Parrales V, Vasili E, et al., Outeiro TF. "Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo", Neurobiology of Disease. 2021;151:105256. doi:10.1016/j.nbd.2021.105256. PMID 33429042. H4, SH-SY5Y and HEK293 cells, RT-QuIC seeding assay and C. elegans; lower mitochondrial ROS.
  52. ↑ Santos-Lobato BL, Brito MMCM, Pimentel ÂV, Cavalcanti RTO, Del-Bel E, Tumas V. "Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study", Arquivos de Neuro-Psiquiatria. 2023;81(5):460-468. doi:10.1055/s-0043-1768668. PMID 37257466. PMC10232028. Open-label, uncontrolled, single-arm phase 2; n=8; 200 mg/day for 12 weeks; UDysRS Friedman χ2 = 9.6,; ON time with troublesome dyskinesia χ2 = 10.8,; no severe adverse events, dyspepsia most common.
  53. ↑ Erhardt EB, Mayer AR, Lin HC, et al., Ryman SG. "The influence of intermittent hypercapnia on cerebrospinal fluid flow and clearance in Parkinson's disease and healthy older adults", NPJ Parkinsons Disease. 2025;11:334. PMID 41271795. Human experimental study; plasma markers raised: total α-synuclein, neurofilament light, GFAP, amyloid β1-42 and β1-40, p-tau217.
  54. ↑ Nadeev AD, Kritskaya KA, Fedotova EI, Berezhnov AV. "«One Small Step for Mouse»: High CO(2) Inhalation as a New Therapeutic Strategy for Parkinson's Disease", Biomedicines. 2022;10(11):2832. doi:10.3390/biomedicines10112832. PMID 36359351. PMC9687253. Proposed mechanism: mitophagy via transient brain acidification.
  55. ↑ @pikeypilled, 22 July 2026; bath method [1]; dosing 100 mg twice daily tapered to 25 mg/day, improvement within 1 to 1.5 weeks of adding doxycycline [2]; high-dose thiamine before CO₂ had no effect [3].